AlphaQuest LLC grew its position in shares of Liquidia Corporation (NASDAQ:LQDA – Free Report) by 4,240.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 17,753 shares of the company’s stock after buying an additional 17,344 shares during the quarter. AlphaQuest LLC’s holdings in Liquidia were worth $404,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in LQDA. Opaleye Management Inc. raised its holdings in Liquidia by 9.5% during the second quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock worth $30,838,000 after purchasing an additional 215,000 shares in the last quarter. Geode Capital Management LLC grew its holdings in Liquidia by 2.4% during the second quarter. Geode Capital Management LLC now owns 1,405,747 shares of the company’s stock worth $17,517,000 after acquiring an additional 32,499 shares during the period. Tyro Capital Management LLC acquired a new position in shares of Liquidia during the 2nd quarter worth $15,473,000. CenterBook Partners LP lifted its stake in shares of Liquidia by 811.7% in the second quarter. CenterBook Partners LP now owns 1,103,850 shares of the company’s stock valued at $13,754,000 after purchasing an additional 982,778 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in Liquidia by 10.7% during the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock worth $12,703,000 after buying an additional 82,955 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.
Insider Buying and Selling at Liquidia
In related news, insider Jason Adair sold 35,656 shares of the firm’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $30.03, for a total transaction of $1,070,749.68. Following the completion of the sale, the insider directly owned 174,998 shares of the company’s stock, valued at approximately $5,255,189.94. This trade represents a 16.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Roger Jeffs sold 66,610 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $2,493,212.30. Following the completion of the transaction, the chief executive officer directly owned 1,037,528 shares of the company’s stock, valued at approximately $38,834,673.04. The trade was a 6.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 252,476 shares of company stock valued at $9,173,435. 26.50% of the stock is owned by company insiders.
Analysts Set New Price Targets
Get Our Latest Analysis on LQDA
Liquidia Trading Up 3.6%
Shares of LQDA stock opened at $43.04 on Friday. The firm’s 50-day simple moving average is $36.69 and its 200-day simple moving average is $28.92. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96. Liquidia Corporation has a 1-year low of $11.26 and a 1-year high of $46.67. The firm has a market cap of $3.74 billion, a P/E ratio of -29.89, a PEG ratio of 1.17 and a beta of 0.46.
About Liquidia
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Featured Articles
- Five stocks we like better than Liquidia
- NEW LAW: Congress Approves Setup For Digital Dollar?
- The day the gold market broke
- What a Former CIA Agent Knows About the Coming Collapse
- Your Bank Account Is No Longer Safe
- He just nailed another gold prediction …
Want to see what other hedge funds are holding LQDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Liquidia Corporation (NASDAQ:LQDA – Free Report).
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
